EP2658868A4 - Analyse par srm/mrm de protéines her3 - Google Patents
Analyse par srm/mrm de protéines her3Info
- Publication number
- EP2658868A4 EP2658868A4 EP11852979.1A EP11852979A EP2658868A4 EP 2658868 A4 EP2658868 A4 EP 2658868A4 EP 11852979 A EP11852979 A EP 11852979A EP 2658868 A4 EP2658868 A4 EP 2658868A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- mrm assay
- her3 protein
- protein srm
- srm
- her3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000003556 assay Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201061428147P | 2010-12-29 | 2010-12-29 | |
PCT/US2011/067998 WO2012092531A1 (fr) | 2010-12-29 | 2011-12-29 | Analyse par srm/mrm de protéines her3 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2658868A1 EP2658868A1 (fr) | 2013-11-06 |
EP2658868A4 true EP2658868A4 (fr) | 2015-08-12 |
EP2658868B1 EP2658868B1 (fr) | 2019-07-17 |
Family
ID=46383544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11852979.1A Active EP2658868B1 (fr) | 2010-12-29 | 2011-12-29 | Analyse par srm/mrm de protéines her3 |
Country Status (7)
Country | Link |
---|---|
US (2) | US9128102B2 (fr) |
EP (1) | EP2658868B1 (fr) |
JP (1) | JP6047503B2 (fr) |
AU (2) | AU2011351992A1 (fr) |
CA (1) | CA2823337C (fr) |
ES (1) | ES2738867T3 (fr) |
WO (1) | WO2012092531A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6412100B2 (ja) * | 2013-03-15 | 2018-10-24 | エクスプレッション、パソロジー、インコーポレイテッドExpression Pathology, Inc. | 癌療法を示すためのsrmアッセイ |
KR20190080973A (ko) * | 2014-07-11 | 2019-07-08 | 익스프레션 패톨로지, 인크. | GTPase KRas 단백질(KRas)에 대한 SRM/MRM 검정 |
WO2016007968A2 (fr) * | 2014-07-11 | 2016-01-14 | Expression Pathology, Inc. | Dosage srm/mrm de la protéine du membre 8 de la superfamille des récepteurs du facteur de nécrose tumorale (cd30) |
CA2954689A1 (fr) * | 2014-07-11 | 2016-01-14 | Expression Pathology, Inc. | Dosage par srm/mrm de la proteine serine/threonine kinase b-raf (braf) |
AU2016262631A1 (en) | 2015-05-14 | 2017-11-30 | Expression Pathology, Inc. | SRM/MRM assay for the fibroblast growth factor receptor 2 (FGFR2) protein |
WO2018223121A1 (fr) * | 2017-06-02 | 2018-12-06 | Expression Pathology, Inc. | Prédiction de résultat de traitement du cancer par t-dm1 |
KR102316892B1 (ko) * | 2019-12-20 | 2021-10-27 | 주식회사 베르티스 | 암의 진단용 조성물 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006068640A1 (fr) * | 2004-12-21 | 2006-06-29 | Cell Signaling Technology, Inc. | Phosphorylation des protéines suivant des voies contrôlées par les egfr |
US20090099340A1 (en) * | 2007-10-12 | 2009-04-16 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
WO2010083252A2 (fr) * | 2009-01-14 | 2010-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Biomarqueurs basés sur des taux et méthodes d'utilisation associées |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7125680B2 (en) * | 2001-07-27 | 2006-10-24 | The Regents Of The University Of California | Methods and materials for characterizing and modulating interaction between heregulin and HER3 |
US7501286B2 (en) | 2002-08-14 | 2009-03-10 | President And Fellows Of Harvard College | Absolute quantification of proteins and modified forms thereof by multistage mass spectrometry |
AU2003302821B2 (en) | 2002-12-11 | 2009-05-07 | Cell Signaling Technology, Inc. | Method for predicting the response to HER2-directed therapy |
US7807789B2 (en) * | 2004-12-21 | 2010-10-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in EGFR-signaling pathways |
GB0509748D0 (en) * | 2005-05-13 | 2005-06-22 | Univ Glasgow | Materials and methods relating to cell based therapies |
US8609345B2 (en) * | 2005-05-25 | 2013-12-17 | Expression Pathology Incorporated | Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations |
AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
KR20090057936A (ko) * | 2006-02-08 | 2009-06-08 | 타게티드 몰레큘라 다이아그노스틱스, 엘엘씨 | 2가 erbb 리간드 결합 분자 및 그의 제조 방법 및 사용방법 |
EP2447360A1 (fr) * | 2006-04-14 | 2012-05-02 | Cell Signaling Technology, Inc. | Défauts de gène et ALK kinase mutante dans des tumeurs solides humaines |
CN101466721B (zh) | 2007-04-13 | 2013-08-21 | 细胞信号技术公司 | 在人实体瘤中的基因缺损和突变体alk激酶 |
JP2010530980A (ja) * | 2007-06-22 | 2010-09-16 | エクスプレッション、パソロジー、インコーポレイテッド | 固体組織から疾患の分泌バイオマーカーを発見および解析する方法 |
-
2011
- 2011-12-29 WO PCT/US2011/067998 patent/WO2012092531A1/fr active Application Filing
- 2011-12-29 EP EP11852979.1A patent/EP2658868B1/fr active Active
- 2011-12-29 AU AU2011351992A patent/AU2011351992A1/en not_active Abandoned
- 2011-12-29 CA CA2823337A patent/CA2823337C/fr active Active
- 2011-12-29 JP JP2013547689A patent/JP6047503B2/ja active Active
- 2011-12-29 ES ES11852979T patent/ES2738867T3/es active Active
-
2013
- 2013-07-01 US US13/932,883 patent/US9128102B2/en active Active
-
2015
- 2015-09-08 US US14/847,936 patent/US9869680B2/en active Active
-
2017
- 2017-03-03 AU AU2017201499A patent/AU2017201499B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006068640A1 (fr) * | 2004-12-21 | 2006-06-29 | Cell Signaling Technology, Inc. | Phosphorylation des protéines suivant des voies contrôlées par les egfr |
US20090099340A1 (en) * | 2007-10-12 | 2009-04-16 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
WO2010083252A2 (fr) * | 2009-01-14 | 2010-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Biomarqueurs basés sur des taux et méthodes d'utilisation associées |
Non-Patent Citations (6)
Title |
---|
BECKER K-F ET AL: "Quantitative protein analysis from formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis", JOURNAL OF PATHOLOGY, JOHN WILEY & SONS LTD, GB, vol. 211, no. 3, 1 February 2007 (2007-02-01), pages 370 - 378, XP002515221, ISSN: 0022-3417, DOI: 10.1002/PATH.2107 * |
NIROSHINI J. NIRMALAN ET AL: "Initial Development and Validation of a Novel Extraction Method for Quantitative Mining of the Formalin-Fixed, Paraffin-Embedded Tissue Proteome for Biomarker Investigations", JOURNAL OF PROTEOME RESEARCH, vol. 10, no. 2, 30 November 2010 (2010-11-30), pages 896 - 906, XP055169284, ISSN: 1535-3893, DOI: 10.1021/pr100812d * |
RUSH J ET AL: "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 23, no. 1, 1 January 2005 (2005-01-01), pages 94 - 101, XP002322741, ISSN: 1087-0156, DOI: 10.1038/NBT1046 * |
See also references of WO2012092531A1 * |
TAYLOR P ET AL: "PP118 Detection and quantification of EGF receptor phosphorylation in formalin-fixed tumor sections by selected/multiple reaction monitoring mass spectrometry", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 7, no. 4, 1 October 2009 (2009-10-01), pages 31, XP026692231, ISSN: 1359-6349, [retrieved on 20091001], DOI: 10.1016/S1359-6349(09)72213-X * |
THOMAS KOCHER ET AL: "High Precision Quantitative Proteomics Using iTRAQ on an LTQ Orbitrap: A New Mass Spectrometric Method Combining the Benefits of All", JOURNAL OF PROTEOME RESEARCH, vol. 8, no. 10, 2 October 2009 (2009-10-02), pages 4743 - 4752, XP055170630, ISSN: 1535-3893, DOI: 10.1021/pr900451u * |
Also Published As
Publication number | Publication date |
---|---|
JP6047503B2 (ja) | 2016-12-21 |
AU2011351992A1 (en) | 2013-07-18 |
CA2823337A1 (fr) | 2012-07-05 |
US9128102B2 (en) | 2015-09-08 |
US9869680B2 (en) | 2018-01-16 |
US20150369818A1 (en) | 2015-12-24 |
WO2012092531A1 (fr) | 2012-07-05 |
AU2017201499B2 (en) | 2018-09-13 |
CA2823337C (fr) | 2019-09-10 |
JP2014505870A (ja) | 2014-03-06 |
ES2738867T3 (es) | 2020-01-27 |
AU2017201499A1 (en) | 2017-03-30 |
EP2658868A1 (fr) | 2013-11-06 |
US20130289142A1 (en) | 2013-10-31 |
EP2658868B1 (fr) | 2019-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2659267A4 (fr) | Essai srm/mrm sur protéine cmet | |
HK1218558A1 (zh) | 蛋白 | |
EP2536818A4 (fr) | Dosage immunomultiplex à billes immobilisées | |
EP2649192A4 (fr) | Dosage de her2 srm/mrm tronqué | |
GB0903469D0 (en) | Assay | |
EP2612913A4 (fr) | Nouvelle protéine hydrolase | |
EP2658868A4 (fr) | Analyse par srm/mrm de protéines her3 | |
IL255077A0 (en) | srm/mrm test for bcl-2-like protein 11 | |
GB0918712D0 (en) | An assay | |
IL194940A0 (en) | Protein assay | |
IL240134A0 (en) | new proteins | |
IL233569A0 (en) | srm/srm test for the insulin receptor protein | |
ZA201109283B (en) | Protein | |
GB201021711D0 (en) | Assay | |
GB201004306D0 (en) | Assay | |
GB0904639D0 (en) | Assay | |
GB0902565D0 (en) | Assay | |
GB201002382D0 (en) | Assay | |
EP2660603A4 (fr) | Procédé d'essai immunologique | |
GB0921873D0 (en) | Assay | |
EP2639302A4 (fr) | Protéine fluorescente modifiée | |
GB0913773D0 (en) | Assay | |
GB201020821D0 (en) | Complement protein assay | |
GB201011997D0 (en) | Assay | |
GB201010226D0 (en) | Assay |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20130729 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/74 20060101ALI20150319BHEP Ipc: G01N 33/574 20060101ALI20150319BHEP Ipc: G01N 33/68 20060101ALI20150319BHEP Ipc: C07K 16/18 20060101AFI20150319BHEP |
|
RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20150710 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/68 20060101ALI20150706BHEP Ipc: G01N 33/574 20060101ALI20150706BHEP Ipc: C07K 16/18 20060101AFI20150706BHEP Ipc: G01N 33/74 20060101ALI20150706BHEP |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: EXPRESSION PATHOLOGY, INC. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20161108 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20170725 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
INTC | Intention to grant announced (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20180122 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
INTC | Intention to grant announced (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20180806 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
INTC | Intention to grant announced (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20190125 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602011060579 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1155769 Country of ref document: AT Kind code of ref document: T Effective date: 20190815 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: ISLER AND PEDRAZZINI AG, CH |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20190717 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1155769 Country of ref document: AT Kind code of ref document: T Effective date: 20190717 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2738867 Country of ref document: ES Kind code of ref document: T3 Effective date: 20200127 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191017 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190717 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191118 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191017 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190717 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190717 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190717 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190717 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190717 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190717 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190717 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190717 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191117 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191018 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190717 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190717 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190717 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190717 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190717 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190717 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200224 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190717 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190717 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602011060579 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG2D | Information on lapse in contracting state deleted |
Ref country code: IS |
|
26N | No opposition filed |
Effective date: 20200603 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20191231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190717 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190717 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191229 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191231 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20201221 Year of fee payment: 10 Ref country code: FR Payment date: 20201223 Year of fee payment: 10 Ref country code: GB Payment date: 20201223 Year of fee payment: 10 Ref country code: IE Payment date: 20201228 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20201224 Year of fee payment: 10 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190717 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20210223 Year of fee payment: 10 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20111229 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190717 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190717 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20211229 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211229 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211229 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211231 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211229 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20230331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211230 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230529 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20231214 Year of fee payment: 13 |